Emerging medication for the treatment of male hypogonadism

Bibliography

• Petak SM, Nankin HR, Spark RF, American Association of Clinical Endocrinologists. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update. Endocr Pract 2002;8:440-56
   PubMedGoogle Scholar
• Lenzi A, Balercia G, Bellastella A, Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 2009;32:934-8
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-54
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011;10:778-92
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Morelli A, Corona G, Filippi S, Which patients with sexual dysfunction are suitable for testosterone replacement therapy. J Endocrinol Invest 2007;30:880-8
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
   PubMed Web of Science ®Google Scholar
• Buvat J, Maggi M, Gooren L, Endocrine aspects of male sexual dysfunctions. J Sex Med 2010;7:1627-56
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff R, Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009;55:121-30
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35
   PubMed Web of Science ®Google Scholar
• Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006;18:236-50
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Petrone L, ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006;3:706-15
   PubMed Web of Science ®Google Scholar
• Liu PY, Baker HW, Jayadev V, Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009;94:801-8
   PubMed Web of Science ®Google Scholar
• Farhat R, Al-zidjali F, Alzahrani AS. Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism. Pituitary 2010;13(2):105-10
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Celermajer DS, Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003;148:55-66
   PubMed Web of Science ®Google Scholar
• Cailleux-Bounacer A, Reznik Y, Cauliez B, Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men. Eur J Endocrinol 2008;159:171-8
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-35
   PubMed Web of Science ®Google Scholar
• Meier C, Liu PY, Ly LP, Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004;89:3033-41
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Matsumiya K, Takao T, Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male 2005;8:175-9
   PubMedGoogle Scholar
• Endogenous Hormones and Prostate Cancer Collaborative Group. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75
   PubMed Web of Science ®Google Scholar
• Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl 2006;27:72-8
   PubMed Web of Science ®Google Scholar
• Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 2005;90:2610-17
   PubMed Web of Science ®Google Scholar
• Page ST, Bremner WJ, Clark RV, Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism. J Androl 2008;29:222-7
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-20
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-10
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD, Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005;90:1502-10
   PubMed Web of Science ®Google Scholar
• Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl 2007;28:875-82
   PubMed Web of Science ®Google Scholar
• Page ST, Hirano L, Gilchriest J, Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011;186:191-7
   PubMed Web of Science ®Google Scholar
• Yu YM, Punyasavatsu N, Elder D, Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 1999;104:e23
   PubMed Web of Science ®Google Scholar
• Merhi ZO, Santoro N. Postmenopausal virilization after spousal use of topical androgens. Fertil Steril 2007;87:976- e13-15
   PubMedGoogle Scholar
• Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old-boy induced by indirect topical exposure to testosterone. Clin Pediatr (Phila) 2007;46:540-3
   PubMed Web of Science ®Google Scholar
• Mazer N, Fisher D, Fischer J, Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J Sex Med 2005;2:227-34
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Miller MG, Garwin JL, Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011;8:2079-89
   PubMed Web of Science ®Google Scholar
• Miller J, Britto M, Fitzpatrick S, Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism. Endocr Pract 2011;17:574-83
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Miller MG, Fitzpatrick S, One-Year Efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med 2012; Epub ahead of print
   PubMedGoogle Scholar
• Stahlman J, Britto M, Fitzpatrick S, Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr Med Res Opin 2012;28:291-301
   PubMed Web of Science ®Google Scholar
• Stahlman J, Britto M, Fitzpatrick S, Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. Curr Med Res Opin 2012;28:281-90
   PubMed Web of Science ®Google Scholar
• Stahlman J, Britto M, Fitzpatrick S, Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel. Curr Med Res Opin 2012;28:271-9
   PubMed Web of Science ®Google Scholar
• Wang C, Ilani N, Arver S, Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol 2011;75(6):836-43
   PubMed Web of Science ®Google Scholar
• Maggi M, Buvat J, Corona G, Hormonal Causes of Male sexual dysfunctions and their management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, DHEA). J Sex Med 2012; In press
   Web of Science ®Google Scholar
• Yen SS. Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. Proc Natl Acad Sci USA 2001;98:8167-9
   PubMed Web of Science ®Google Scholar
• Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003;21:346-55
   PubMed Web of Science ®Google Scholar
• Baulieu EE, Thomas G, Legrain S, Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-84
   PubMed Web of Science ®Google Scholar
• Nair KS, Rizza RA, O'Brien P, DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-59
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011;165:687-701
   PubMed Web of Science ®Google Scholar
• Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006;4:CD006221
   PubMedGoogle Scholar
• Nissen SL, Sharp RL. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. J Appl Physiol 2003;94:651-9
   PubMed Web of Science ®Google Scholar
• Choi SK, Han SW, Kim DH, De Lignieres B. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 1993;150(2 Pt 2):657-60
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin Endocrinol Metab 1998;12:501-6
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002;87:1462-6
   PubMed Web of Science ®Google Scholar
• Chemana D, Morville R, Fiet J, Percutaneous absorption of 5 alpha-dihydrotestosterone in man. II. Percutaneous administration of 5 alpha-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. Int J Androl 1982;5:595-606
   PubMed Web of Science ®Google Scholar
• Ly LP, Jimenez M, Zhuang TN, A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:4078-88
   PubMed Web of Science ®Google Scholar
• Simon D, Charles MA, Lahlou N, Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001;24:2149-51
   PubMed Web of Science ®Google Scholar
• Kunelius P, Lukkarinen O, Hannuksela ML, The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467-72
   PubMed Web of Science ®Google Scholar
• Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl 2003;24:568-76
   PubMed Web of Science ®Google Scholar
• Barud W, Palusinski R, Makaruk B, Dihydrotestosterone treatment in men with coronary artery disease. II. Influence on myocardial ischemia and left ventricle. Ann Univ Mariae Curie Sklodowska Med 2003;58:247-52
   PubMedGoogle Scholar
• Barud W, Palusinski R, Makaruk B, Hanzlik J. Dihydrotestosterone treatment in men with coronary artery disease. I. Influence on sex hormones, lipid profile, insulin resistance and fibrinogen. Ann Univ Mariae Curie Sklodowska Med 2003;58:241-6
   PubMedGoogle Scholar
• Luisi M, Franchi F. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 1980;3:305-8
   PubMed Web of Science ®Google Scholar
• Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997;2:293-8
   PubMedGoogle Scholar
• Jockenhovel F, Bullmann C, Schubert M, Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999;48:590-6
   PubMed Web of Science ®Google Scholar
• Schubert M, Bullmann C, Minnemann T, Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003;60(1):21-8
   PubMed Web of Science ®Google Scholar
• Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs 2009;18:1947-55
   PubMed Web of Science ®Google Scholar
• Filippi S, Luconi M, Granchi S, Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 2002;143:4271-80
   PubMed Web of Science ®Google Scholar
• Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006;12:6315s-9s
   PubMed Web of Science ®Google Scholar
• Shabsigh A, Kang Y, Shabsigh R, Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med 2005;2:716-21
   PubMed Web of Science ®Google Scholar
• Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80:3546-52
   PubMed Web of Science ®Google Scholar
• Guay AT, Jacobson J, Perez JB, Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003;15:156-65
   PubMed Web of Science ®Google Scholar
• Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 2009;161:163-9
   PubMed Web of Science ®Google Scholar
• Ribeiro RS, Abucham J. Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas. Arq Bras Endocrinol Metabol 2011;55:266-71
   PubMed Web of Science ®Google Scholar
• Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006;86:1664-8
   PubMed Web of Science ®Google Scholar
• Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976;43:1370-7
   PubMed Web of Science ®Google Scholar
• Landefeld CS, Schambelan M, Kaplan SL, Embury SH. Clomiphene-responsive hypogonadism in sickle cell anemia. Ann Intern Med 1983;99:480-3
   PubMed Web of Science ®Google Scholar
• Bjork JT, Varma RR, Borkowf HI. Clomiphene citrate therapy in a patient with Laennec's cirrhosis. Gastroenterology 1977;72:1308-11
   PubMed Web of Science ®Google Scholar
• Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 2003;79:203-5
   PubMed Web of Science ®Google Scholar
• Ronnberg L, Reinila M, Ylikorkala O. Effects of experimental hyperprolactinemia and clomiphene on pituitary responsiveness to LHRH and TRH in men. Andrologia 1985;17:364-8
   PubMed Web of Science ®Google Scholar
• Moreira AC, Verissimo JM, Foss MC, Pubertal maturation of the LH stimulatory response to clomiphene citrate in congenital virilizing adrenal hyperplasia. Clin Endocrinol (Oxf) 1982;17:441-7
   PubMed Web of Science ®Google Scholar
• Kulin HE, Grumbach MM, Kaplan SL. Gonadal-hypothalamic interaction in prepubertal and pubertal man: effect of clomiphene citrate on urinary follicle-stimulating hormone and luteinizing hormone and plasma testosterone. Pediatr Res 1972;6:162-71
   PubMed Web of Science ®Google Scholar
• Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal. Int Urol Nephrol 2009; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy for idiopathic male infertility: a survey of the american urological association. J Urol 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003;52:1126-8
   PubMed Web of Science ®Google Scholar
• De Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005;7:211-15
   PubMed Web of Science ®Google Scholar
• Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008;158:741-7
   PubMed Web of Science ®Google Scholar
• Richardson D, Goldmeier D, Frize G, Letrozole versus testosterone. A single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med 2007;4:502-8
   PubMed Web of Science ®Google Scholar
• Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int 2005;16:1487-94
   PubMed Web of Science ®Google Scholar
• Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011;95:(2)809-11
   PubMed Web of Science ®Google Scholar
• Cavallini G, Beretta G, Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH. Asian J Androl 2011;13:895-7
   PubMed Web of Science ®Google Scholar
• Voigt KD, Bartsch W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 1986;25(5B):749-57
   PubMedGoogle Scholar
• Kuiper GG, Carlsson B, Grandien K, Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-70
   PubMed Web of Science ®Google Scholar
• Murphy JB, Emmott RC, Hicks LL, Walsh PC. Estrogen receptors in the human prostate, seminal vesicle, epididymis, testis, and genital skin: a marker for estrogen-responsive tissues? J Clin Endocrinol Metab 1980;50:938-48
   PubMed Web of Science ®Google Scholar
• Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000;24:145-55
   PubMed Web of Science ®Google Scholar
• Enmark E, Pelto-Huikko M, Grandien K, Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Luconi M, Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility. Endocrinology 2004;145:1823-34
   PubMed Web of Science ®Google Scholar
• Velders M, Schleipen B, Fritzemeier KH, Selective estrogen receptor-beta activation stimulates skeletal muscle growth and regeneration. FASEB J 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011;10:778-92
   PubMed Web of Science ®Google Scholar
• Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010;118:246-51
   Google Scholar
• McPherson SJ, Ellem SJ, Simpson ER, Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007;148(2):566-74
   PubMed Web of Science ®Google Scholar
• McPherson SJ, Hussain S, Balanathan P, Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.. Proc Natl Acad Sci USA 2010;107(7):3123-8
   PubMed Web of Science ®Google Scholar
• Muthusamy S, Andersson S, Kim HJ, Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA 2011;108:20090-4
   PubMed Web of Science ®Google Scholar
• Prasad PV, Arumugam R, Willman M, Distribution, metabolism and excretion of a synthetic androgen 7alpha-methyl-19-nortestosterone, a potential male-contraceptive. Steroids 2009;74:121-31
   PubMed Web of Science ®Google Scholar
• Anderson RA, Martin CW, Kung AWC, 7-Methyl-19-nortestosterone (MENT) maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999;84:3556-62
   PubMed Web of Science ®Google Scholar
• Cummings DE, Kumar N, Bardin CW, Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998;83:4212-19
   PubMed Web of Science ®Google Scholar
• Anderson RA, Wallace AM, Sattar N, Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 2003;88:2784-93
   PubMed Web of Science ®Google Scholar
• Attardi BJ, Hild SA, Koduri S, The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. J Steroid Biochem Mol Biol 2010;122:212-18
   PubMed Web of Science ®Google Scholar
• Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Dalton JT, Barnette KG, Bohl CE, The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153-61
   PubMed Web of Science ®Google Scholar
• Maggi M, Schulman C, Quinton R, The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007;4(4 Pt 1):1056-69
   PubMed Web of Science ®Google Scholar